World Health Report 2004: changing history. WHO; 2004.
Arvind BA, Gururaj G, Loganathan S, Amudhan S, Varghese M, Benegal V, et al. Prevalence and socioeconomic impact of depressive disorders in India: Multisite population-based cross-sectional study. BMJ Open. 2019;9(6):e027250. https://doi.org/10.1136/bmjopen-2018-027250.
Article
PubMed
PubMed Central
Google Scholar
Dhar AK, Barton DA. Depression and the link with cardiovascular disease. Front Psychiatry. 2016;7(MAR):1.
Google Scholar
Xin LM, Chen L, Su YA, Yang FD, Wang G, Fang YR, et al. Risk factors for recent suicide attempts in major depressive disorder patients in China: results from a National Study. Front Psychiatry. 2018;9:300. https://doi.org/10.3389/fpsyt.2018.00300.
Article
PubMed
PubMed Central
Google Scholar
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):2011–30.
Article
Google Scholar
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(Suppl 1):1–21.
Article
CAS
Google Scholar
Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96. https://doi.org/10.1177/0269881107088441.
Article
CAS
PubMed
Google Scholar
Lalit V, Appaya PM, Hegde RP, Mital AK, Mittal S, Nagpal R, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian J Psychiatry. 2004;46(4):333–41.
PubMed
PubMed Central
Google Scholar
Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2012;6:853–61. https://doi.org/10.2147/PPA.S22495.
Article
PubMed
PubMed Central
Google Scholar
Boulenger JP, Huusom AKT, Florea I, Bæmadraskdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006;22(7):1331–41. https://doi.org/10.1185/030079906X115513.
Article
CAS
PubMed
Google Scholar
Jiang K, Li L, Wang X, Fang M, Shi J, Cao Q, et al. Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: A 24-week, open-label, prospective study in Chinese population. Neuropsychiatr Dis Treat. 2017;13:515–26. https://doi.org/10.2147/NDT.S120190.
Article
CAS
PubMed
PubMed Central
Google Scholar
Grover S, Avasth A, Kalita K, Dalal P, Rao G, Chadda R, et al. IPS multicentric study: antidepressant prescription patterns. Indian J Psychiatry. 2013;55(1):41–5. https://doi.org/10.4103/0019-5545.105503.
Article
PubMed
PubMed Central
Google Scholar
Steimer W. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit. 2010;32(4):381–6. https://doi.org/10.1097/FTD.0b013e3181e1a78d.
Article
CAS
PubMed
Google Scholar
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–59. https://doi.org/10.1016/S0006-3223(03)00231-2.
Article
PubMed
Google Scholar
Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–32. https://doi.org/10.1016/j.jad.2015.09.033.
Article
PubMed
Google Scholar
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70. https://doi.org/10.4088/JCP.v68n0713.
Article
PubMed
Google Scholar
Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. J Am Med Assoc. 2002;288(11):1403–9. https://doi.org/10.1001/jama.288.11.1403.
Article
Google Scholar
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289–304. https://doi.org/10.1016/S0149-2918(03)80220-5.
Article
CAS
PubMed
Google Scholar
Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015;171:137–41. https://doi.org/10.1016/j.jad.2014.09.020.
Article
CAS
PubMed
Google Scholar
Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36(2):87–113. https://doi.org/10.1503/jpn.100059.
Article
PubMed
PubMed Central
Google Scholar
Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr. 2008;13(12):1066–86. https://doi.org/10.1017/S1092852900017120.
Article
PubMed
Google Scholar
Locher C, Kossowsky J, Gaab J, Kirsch I, Bain P, Krummenacher P. Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: A systematic review and meta-analysis. J Affect Disord. 2015;181:50–60. https://doi.org/10.1016/j.jad.2015.03.062.
Article
CAS
PubMed
Google Scholar
Association AP. Association, AP Diagnostic and statistical manual of mental disorders. 1995.
Google Scholar
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154.
Article
CAS
PubMed
Google Scholar
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32.
CAS
PubMed
Google Scholar
Patel M, Patel V, Tiwari D, Shah VR, Patel D, Chanpa N. Efficacy and safety of escitalopram in first episode of major depressive disorder - a tertiary care Indian center experience. J Depress anxiety. 2018;7:1–5.
Article
Google Scholar
Pinto C, Trivedi JK, Vankar GK, Sharma PS, Narasimha V. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. J Indian Med Assoc. 2007;105(7):364–8.
PubMed
Google Scholar
Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety. 2008;25(1):46–54. https://doi.org/10.1002/da.20222.
Article
CAS
PubMed
Google Scholar
Li G, Shen Y, Luo J, Li H. Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: a pooled analysis of 4 Chinese clinical trials. Medicine. 2017;96(39):e8142. https://doi.org/10.1097/MD.0000000000008142.
Article
CAS
PubMed
PubMed Central
Google Scholar
Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin. 2005;21(10):1659–68. https://doi.org/10.1185/030079905X65484.
Article
CAS
PubMed
Google Scholar
Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002;17(3):95–102. https://doi.org/10.1097/00004850-200205000-00001.
Article
CAS
PubMed
Google Scholar
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;2:CD006532.
Google Scholar
Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;11(1):42. https://doi.org/10.1186/1471-244X-11-42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. https://doi.org/10.1176/appi.ajp.163.1.28.
Article
PubMed
Google Scholar
Joffe RT, Young LT, Levitt AJ, MacQueen G, Marriott MJ, Robb J. Number of episodes and antidepressant response in major depression. Int J Neuropsychopharmacol. 1999;2(2):111–3. https://doi.org/10.1017/S1461145799001443.
Article
PubMed
Google Scholar
Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry. 2008;165(3):342–51. https://doi.org/10.1176/appi.ajp.2007.06111868.
Article
PubMed
Google Scholar
Mulder RT, Watkins WGA, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord. 2003;76(1–3):143–9. https://doi.org/10.1016/S0165-0327(02)00083-6.
Article
CAS
PubMed
Google Scholar
Lopez-Castroman J, Jaussent I, Gorwood P, Courtet P. Suicidal depressed patients respond less well to antidepressants in the short term. Depress Anxiety. 2016;33(6):483–94. https://doi.org/10.1002/da.22473.
Article
CAS
PubMed
Google Scholar
Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396. https://doi.org/10.1136/bmj.330.7488.396.
Article
CAS
PubMed
PubMed Central
Google Scholar
Isacsson G, Rich CL, Jureidini J, Raven M. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br J Psychiatry. 2010;196(6):429–33. https://doi.org/10.1192/bjp.bp.109.076166.
Article
PubMed
Google Scholar
Griffiths JJ, Zarate CA Jr, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med. 2014;47(3 Suppl 2):S195–203. https://doi.org/10.1016/j.amepre.2014.06.012.
Article
PubMed
PubMed Central
Google Scholar
Ozdilek B. Escitalopram-induced bradycardia in elderly individuals: a case series report. Klin Psikofarmakol Bul. 2015;25(2):183–5. https://doi.org/10.5455/bcp.20140304090654.
Article
Google Scholar
Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391–400. https://doi.org/10.1016/j.euroneuro.2013.05.011.
Article
CAS
PubMed
Google Scholar
Shinde M, Reddy P, Kulmi M, Goyal C. Efficacy and tolerability of milnacipran and escitalopram: a comparative study among patients of depression. Int J Basic Clin Pharmacol. 2018;7(5):839. https://doi.org/10.18203/2319-2003.ijbcp20181489.
Article
Google Scholar
Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003;167(4):353–62. https://doi.org/10.1007/s00213-002-1364-z.
Article
CAS
PubMed
Google Scholar
Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012;219(1):1–13. https://doi.org/10.1007/s00213-011-2463-5.
Article
CAS
PubMed
Google Scholar
Culpepper L. Escitalopram: A new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry. 2002;4(6):209–14. https://doi.org/10.4088/PCC.v04n0601.
Article
PubMed
PubMed Central
Google Scholar
Basu A, Chadda RK, Sood M, Kaur H, Kukreti R. A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population suffering from Major Depressive Disorder (MDD). Asian J Psychiatr. 2019;43:184–8. https://doi.org/10.1016/j.ajp.2019.05.028.
Article
PubMed
Google Scholar
Mandal T, Bairy LK, Sharma PSVN. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population. Eur J of Clin Pharmacol. 2020;76(6):807–14. https://doi.org/10.1007/s00228-020-02866-4.
Article
Google Scholar
Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11(4):537–46. https://doi.org/10.2217/pgs.09.168.
Article
CAS
PubMed
Google Scholar
Rajkumar R, Kashyap VK. Genetic structure of four socio-culturally diversified caste populations of southwest India and their affinity with related Indian and global groups. BMC Genet. 2004;5(1):23. https://doi.org/10.1186/1471-2156-5-23.
Article
PubMed
PubMed Central
Google Scholar